

Drug Monograph

Drug/Drug **Afrezza™ (insulin human) powder for inhalation/ Rapid**
Class: **Acting Insulins**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Afrezza™ is now available in a package containing 90 cartridges. 60 cartridges that contain 8 units each and 30 cartridges that contain 12 units each of human insulin. Each package comes with 2 inhalers.

Manufacturer: MannKind Corporation, Danbury, CT 06810

Indications: Afrezza™ is rapid acting human insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza™ is not a substitute for long-acting insulin. It must be used in combination with long-acting insulin in patients with type 1 diabetes mellitus.

Costs: \$3.51 per cartridge of Afrezza™. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Under Solicitation
 Appropriate Indications Preferred Agent

Prepared By: Luke Boehmer Pharm.D.
Date: September 2, 2015